[responsivevoice_button voice="Hindi Female" buttontext="Listen This News"]
The board of directors of Natco Pharma has approved the acquisition of an additional shareholding in Adcock Ingram Holdings Proprietary Ltd with an investment of up to ₹1400 crore.
This acquisition is valued at ₹1,069 crore at the prevailing exchange rate and will take Hyderabad-based Natco’s shareholding in Adcock Ingram from 35.75 percent to 49 percent, the company said in a release.
Adcock Ingram has delivered a topline of $423 million with an EBITDA of $59 million for the period ending 9 months on March 31, 2026. Post transaction, NATCO will be recognising 49 percent of profit after tax of Adcock Ingram in its books.